PMID- 35121638
OWN - NLM
STAT- MEDLINE
DCOM- 20220406
LR  - 20220406
IS  - 2056-5933 (Electronic)
IS  - 2056-5933 (Linking)
VI  - 8
IP  - 1
DP  - 2022 Feb
TI  - Effectiveness of electronic drug monitoring feedback to increase adherence in 
      patients with RA initiating a biological DMARD: a randomised clinical trial.
LID - 10.1136/rmdopen-2021-001712 [doi]
LID - e001712
AB  - OBJECTIVE: Medication non-adherence in rheumatoid arthritis (RA) is associated 
      with disease flares, increased disability and increased costs. This study 
      assessed the effectiveness of electronic monitoring feedback (EMF) on medication 
      adherence in patients with RA starting with or switching to a new biological 
      disease-modifying antirheumatic drug (bDMARD). METHODS: In this randomised 
      controlled trial, bDMARD starters were assigned to the intervention or control 
      group and followed for 1 year. The intervention group received a needle container 
      with a Medication Event Monitoring System (MEMS) cap registering patient's 
      adherence to injections. Scores were calculated every 3 months with MEMS and 
      motivational interviewing feedback was given. The control group received usual 
      care. Effectiveness of EMF on adherence was measured with the medication 
      possession ratio (MPR). RESULTS: 104 consecutive intervention patients were 
      included and 102 controls. MPR was 0.95 (SD: 0.10) and 0.90 (0.16) after 12 
      months (B: 0.036, 95% CI: 0.001 to 0.007, p=0.045). bDMARD-naive patients 
      receiving EMF achieved low disease activity (LDA) sooner compared with the 
      control group, adjusted for baseline DAS (HR: 1.68, 95% CI: 1.00 to 2.81, 
      p=0.050). Side effects and DAS28 were similar. CONCLUSION: EMF increased 
      adherence for patients with RA starting with or switching to a bDMARD. Especially 
      bDMARD-naive patients achieved LDA sooner compared with the control group, which 
      holds promise for the future.
CI  - (c) Author(s) (or their employer(s)) 2022. Re-use permitted under CC BY-NC. No 
      commercial re-use. See rights and permissions. Published by BMJ.
FAU - Hebing, Renske Cf
AU  - Hebing RC
AUID- ORCID: 0000-0002-6725-6719
AD  - Rheumatology, Pharmacy, Reade Hoofdlocatie Dr Jan van Breemenstraat, Amsterdam, 
      The Netherlands r.hebing@reade.nl.
FAU - Aksu, Iremnur
AU  - Aksu I
AD  - Reade Hoofdlocatie Dr Jan van Breemenstraat, Amsterdam, The Netherlands.
FAU - Twisk, Jos Wr
AU  - Twisk JW
AD  - Department of Methodology and Applied Biostatistics, Amsterdam UMC Locatie VUmc, 
      Amsterdam, The Netherlands.
FAU - Bos, Wouter
AU  - Bos W
AD  - Rheumatology, Reade Hoofdlocatie Dr Jan van Breemenstraat, Amsterdam, The 
      Netherlands.
FAU - Van den Bemt, Bart
AU  - Van den Bemt B
AD  - Pharmacy, Sint Maartenskliniek Afdeling Reumatologie, Nijmegen, The Netherlands.
FAU - Nurmohamed, Michael T
AU  - Nurmohamed MT
AUID- ORCID: 0000-0002-6274-1934
AD  - Rheumatology and Internal Medicine, Reade Hoofdlocatie Dr Jan van Breemenstraat, 
      Amsterdam, The Netherlands.
LA  - eng
PT  - Journal Article
PT  - Randomized Controlled Trial
PT  - Research Support, Non-U.S. Gov't
PL  - England
TA  - RMD Open
JT  - RMD open
JID - 101662038
RN  - 0 (Antirheumatic Agents)
SB  - IM
MH  - *Antirheumatic Agents/adverse effects
MH  - *Arthritis, Rheumatoid/drug therapy
MH  - Drug Monitoring
MH  - Electronics
MH  - Feedback
MH  - Humans
PMC - PMC8819786
OTO - NOTNLM
OT  - arthritis
OT  - biological therapy
OT  - rheumatoid
OT  - therapeutics
COIS- Competing interests: None declared.
EDAT- 2022/02/06 06:00
MHDA- 2022/04/07 06:00
PMCR- 2022/02/04
CRDT- 2022/02/05 05:48
PHST- 2021/04/26 00:00 [received]
PHST- 2021/09/14 00:00 [accepted]
PHST- 2022/02/05 05:48 [entrez]
PHST- 2022/02/06 06:00 [pubmed]
PHST- 2022/04/07 06:00 [medline]
PHST- 2022/02/04 00:00 [pmc-release]
AID - rmdopen-2021-001712 [pii]
AID - 10.1136/rmdopen-2021-001712 [doi]
PST - ppublish
SO  - RMD Open. 2022 Feb;8(1):e001712. doi: 10.1136/rmdopen-2021-001712.